GlaxoSmithKline (LON: GSK)‘s stock had its “buy” rating restated by equities researchers at Panmure Gordon in a report issued on Wednesday. They currently have a $22.93 (1525 GBX) target price on the stock.
Shares of GlaxoSmithKline opened at 1468.595 on Wednesday. GlaxoSmithKline has a one year low of GBX 1314.00 and a one year high of GBX 1556.50. The stock’s 50-day moving average is currently GBX 1437.31. The company’s market cap is £70.889 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday. They now have a $23.75 price target on the stock. Separately, analysts at JP Morgan Cazenove reiterated an “underweight” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday. They now have a $21.95 price target on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline in a research note to investors on Friday, March 1st. They now have a $21.65 price target on the stock.
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
